medigraphic.com

2016, Number 3

<< Back Next >>

Rev Cuba Endoc 2016; 27 (3)

Body mass index and clinical and pathological characteristics of breast cancer patients

Frontela NM, Gutiérrez AZ, Rubio HMC, Martín RLE, Pérez BIM, Sánchez VI, Valdés PZ, Rodríguez DR

Language: Spanish
References: 73
Page: 45-62
PDF size: 208.80 Kb.


ABSTRACT

Introduction: previous studies have suggested the relationship of the high body mass index with higher incidence and bad prognosis of the breast cancer.
Objective: to determine the relationship between the body mass index at the time of diagnosis of cancer, and the clinical-pathological characteristics of menopausal or non-menopausal breast cancer patients.
Methods: descriptive and cross-sectional study of 47 women aged 36 to 84 years, with invasive duct carcinoma. Their weight and height were taken. Body mass index calculation served to classify the patients into 3 categories: normoweighed, overweighed and obese. The studied clinical-pathological characteristics were size of tumor, presence of metastatic lymph nodes, clinical staging, histological grade and state of estrogen receptor, progesterone receptor and 2 receptor for the epidermal growth factor.
Results: the body mass index changed from 18.54 to 44.92 kg/m2. There were no statistically significant differences among the average overall values of this variable either in premenopausal and postmenopausal women ((26.76 kg/m2 ± 5.26 vs. 28.11 ± 5.61 kg/m2; p= 0.450) or in the analysis by categories. Obesity and overweight were associated to high histological grade both in premenopausal (p= 0.035) and postmenopausal women (p= 0.037). Additionally, a significant association was found between the body mass index and the estrogen or progesterone receptor/receptor 2-positive subtype (for the epidermal growth factor) in postmenopausal women (p= 0.032).
Conclusions: these results show that obese and overweighed women may develop aggressive breast cancer phenotypes regardless of menopause. Moreover, the estrogen or progesterone receptor/receptor 2-positive subtype for the epidermal growth factor prevailed in postmenopausal women with high body mass index. Further studies should be conducted to better understand the relevant factors in the host and the tumor for the prevention and the clinical management of obese patients with breast cancer.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.

  2. Cuba. Minsap. Anuario estadístico de salud. Dirección Nacional de Registros médicos y estadísticas de salud [homepage en Internet]; La Habana, 1998 [citado 13 de abril de 2016]. Disponible en: http://bvs.sld.cu/cgibin/ wxis/anuario/?IsisScript=anuario/iah.xis&tag5003=anuario&tag5021=e&tag600 0=B&tag5013=GUEST&tag5022=1998

  3. Cuba. Minsap. Anuario estadístico de salud. Dirección Nacional de Registros médicos y estadísticas de salud [homepage en Internet]; La Habana, 2004 [citado 13 de abril de 2016]. Disponible en: http://bvs.sld.cu/cgibin/ wxis/anuario/?IsisScript=anuario/iah.xis&tag5003=anuario&tag5021=e&tag600 0=B&tag5013=GUEST&tag5022=2004

  4. Cuba. Minsap. Anuario estadístico de salud. Dirección Nacional de Registros médicos y estadísticas de salud [homepage en Internet]; La Habana, 2014 [citado 13 de abril de 2016]. Disponible en: http://files.sld.cu/bvscuba/files/2015/04/anuario-estadistico-de-salud-2014.pdf

  5. Cuba. Minsap. Anuario estadístico de salud. Dirección Nacional de Registros médicos y estadísticas de salud [homepage en Internet]; La Habana, 2015 [citado 13 de abril de 2016]. Disponible en: http://files.sld.cu/dne/files/2016/04/Anuario_2015_electronico-1.pdf

  6. Bell DW. Our changing view of the genomic landscape of cancer. J Pathol. 2010;220(2):231.

  7. Lippman ME. Cáncer de mama. En: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, eds. Harrison. Principios de Medicina Interna. 19na. edición [libro en Internet]. New York, NY: McGraw-Hill; 2016 [citado 13 de abril de 2016]. Disponible en: http://harrisonmedicina.mhmedical.com/content.aspx?bookid=1717§ionid=114 915085

  8. Velculescu VE. Defining the blueprint of the cancer genome. Carcinogenesis. 2008;29(6):1087.

  9. Copeland NG, Jenkins NA. Deciphering the genetic landscape of cancer-from genes to pathways. Trends Genet. 2009;25(10):455.

  10. Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: De Vita VT, Hellman S, Rosenberg SA. Cancer. Principles and Practice of Oncology. 9th edition. Philadelphia: Lippincott Williams and Wilkins; 2011. p. 4989-5164.

  11. Hankinson SE, Eliassen AH. Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2007;106:24-30.

  12. Golan DE, Tashjian AH, Armstrong EJ. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Baltimore: Wolters Kluwer Health; 2008. p. 701-18.

  13. Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. The Breast. 2014;23:2-9.

  14. Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, et al. Triple negative breast cancer-an overview. HeredGenet. 2013(suppl 2). doi:10.4172/2161-1041.S2-001.

  15. Peña M, Bacallao J. La obesidad en la pobreza: un problema emergente en las Américas. Rev Futuros México. 2005;(3):10.

  16. World Health Organization. The world health report 2002. Reducing risks, promoting healthy life. Geneva: WHO; 2002.

  17. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.

  18. Cairns BJ. Cancer and high body-mass index: global burden, global effort. Lancet Oncol. 2015;16:3-4.

  19. Amadou A, Ferrari P, Muwonge R. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and doseresponse meta-analysis. Obes Rev. 2013;14:665-78.

  20. Yaw YH, Shariff ZM, Kandiah M, Weay YH, Saibul N, Sariman S, et al. Diet and physical activity in relation to weight change among breast cancer patients. Asian Pac J Cancer Prev. 2014;15:39-44.

  21. Montazeri A, Sadighi J, Farzadi F, Maftoon F, Vahdaninia M, Ansari M, et al. Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case-control study. BMC Cancer. 2008;8:278.

  22. Emaus A, Veierød MB, Tretli S, Finstad SE, Selmer R, Furberg AS, et al. Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat. 2010;121:651-60.

  23. Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML, Sternfeld B, et al. Prediagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control. 2008;19:1319-28.

  24. Santillán JG, Mendieta H, Gómez LM, Torres JJ, González JM, Hernández LV, et al. The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA 15-3 are Reliable Biomarkers of Breast Cancer. J Clin Lab Anal. 2013;27:12-20.

  25. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118:5937-46.

  26. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2005;14:2009-14.

  27. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1871-7.

  28. Chlebowski R, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012;30(23):2844-52.

  29. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev. 2013;24(6):503-13.

  30. WHO. Global database on body mass index, BMI classification [homepage en Internet]; 2008 [citado 15 de abril de 2016]. Disponible en: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html&

  31. Kiernan JA. Histological and Histochemical Methods. Theory and Practice. 4th edition. Oxford, UK: Cold Spring Harbor Laboratory Press; 2010. p. 12-141.

  32. Nguyen PL, Taghian AG, Katz MS, Niemierko A, AbiRaad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373-8.

  33. Sobin LH, Wittekind Ch. TNM classification of malignant tumors. 6thed. New York: International Union Against Cancer, Wiley-liss; 2002. p. 131-41.

  34. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52.

  35. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histo-pathology. 1991;19(5):403-10.

  36. Zhu K, Caulfield J, Hunter S, Roland CL, Payne-Wilks K, Texter L. Body mass index and breast cancer risk in African American women. Ann Epidemiol. 2005;15:123-8.

  37. Ewertz M, Jensen MB, Gunnarsdottir KA, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29:25-31.

  38. Kaviani A, Neishaboury M, Mohammadzadeh N, Ansari-Damavandi M, Jamei K. Effects of obesity on presentation of breast cancer, lymph node metastasis and patient survival: a retrospective review. Asian Pac J Cancer Prev. 2013;14:2225-9.

  39. Bouguerra H, Guissouma H, Labidi S, Stambouli N, Marrakchi R, Chouaib S, et al. Breast cancer in Tunisia: association of body mass index with histopathological aspects of tumors. Asian Pacific Journal of Cancer Prevention. 2014;15:6805-10.

  40. Hajian-Tilaki KO, Gholizadehpasha AR, Bozorgzadeh S, Hajian-Tilaki E. Body mass index and waist circumference are predictor biomarkers of breast cancer risk in Iranian women. Med Oncol. 2011;28:1296-301.

  41. Santa-Maria CA, Yan J, Xie XJ, Euhus DM. Aggressive estrogen-receptorpositive breast cancer arising in patients with elevated body mass index. Int J Clin Oncol. 2015;20(2):317-23.

  42. Yanai A, Miyagawa Y, Murase K, Imamura M, Yagi T, Ichii S, et al. Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol. 2014;19:467-72.

  43. Biglia N, Peano E, Sgandurra P, Moggio G, Pecchio S, Maggiorotto F, et al. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol. 2013;29:263-7.

  44. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013;22:344-50.

  45. Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Solak M, et al. Impact of the obesity on lymph node status in operable breast cancer patients. J BUON. 2013;18:824-30.

  46. Singh AK, Pandey A, Tewari M, Pratyush DD, Singh HK, Pandey HP, et al. Obesity augmented breast cancer risk: a potential risk factor for Indian women. J Surg Oncol. 2011;103:217-22.

  47. Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptornegative breast cancer. Breast Cancer Res Treat. 2006;97:245-54.

  48. Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in obesityrelated breast cancer. J Mammary Gland Biol Neoplasia. 2013;18:277-89.

  49. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013;1831:1533-41.

  50. Catalan V, Gomez J, Rodriguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol. 2013;4:275.

  51. Ferguson RD, Gallagher EJ, Scheinman EJ, Damouni R, Le Roith D. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm. 2013;93:51-98.

  52. Simpson ER, Brown KA. Obesity and breast cancer: role of inflammation and aromatase. J Mol Endocrinol. 2013;51:T51-T59.

  53. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia. 2000;5:107-15.

  54. Goodwin PJ, Ennis M, Bahl M, Fantus IG, Pritchard KI, Trudeau ME, et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat. 2009;114:517-25.

  55. Irwin ML, Duggan C, Wang CY, Smith AW, Mc Tiernan A, Baumgartner RN, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011;29:47-53.

  56. Andò S, Barone I, Giordano C, Bonofiglio D, Catalano S. The multifaceted mechanism of Leptin signaling within tumor microenvironment in driving breast cancer growth and progression. Front Oncol. 2014;4:340.

  57. Wang J, Yang DL, Chen ZZ, Gou BF. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: A systematic review and meta-analysis. Cancer Epidemiology. 2016;42:1-8.

  58. Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, et al. Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control. 2016;27(4):459-72.

  59. World Cancer Research Fund and American Institute for Cancer Research. Systematic Literature Review. Continuous Update Report. The Associations between Food, Nutrition and Physical Activity, and the Prevention of Breast Cancer [homepage en Internet]; AICR, 2008 [citado 15 de abril de 2016]. Disponible en: http://www.wcrf.org/

  60. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1871-7.

  61. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nature Review/Cancer. 2015;(15):484-98.

  62. Cuba. Minsap. Factores relacionados con el comportamiento. Proyecciones de Salud Pública de Cuba para el año 2015. La Habana: Editorial Ciencias Médicas; 2006.

  63. Jiménez-Acosta S, Díaz-Sánchez ME, García-Roche RG, Bonet-Gorbea M, Wong- Ordóñez I. Cambios en el estado nutricional de la población cubana adulta de diferentes regiones de Cuba. Rev Cubana Hig Epidemiol. 2012;50(1):4-13.

  64. Bonet-Gorbea M, Varona-Pérez P. III Encuesta Nacional de factores de riesgo y actividades preventivas de enfermedades no transmisibles. Cuba 2010-2011. La Habana: Editorial Ciencias Médicas; 2015.

  65. Hernández M, Porrata C, Jiménez S, Rodríguez A, Carrillo O, García A. Recomendaciones nutricionales para la población cubana. La Habana: Editorial Centro de Documentación e Información Científico-Técnica; 2009.

  66. Maíz GA. Obesidad. Epidemia mundial. Consecuencias patológicas de la obesidad: hipertensión arterial y diabetes mellitus y dislipidemia. Bol Escuela Med [serie en Internet]. 1997 [citado 20 de noviembre de 2015];26(1). Disponible en: http://escuela.med.puc.cl/publ/boletin/obesidad/ConsecuenciasPatologicas.html

  67. Trichopoulou A, Bamia C, Lagiou P, Trichopoulos D. Conformity to traditional Mediterranean diet and breast cancer risk in the Greek EPIC cohort. Am J Clin Nutr. 2010;92:620-5.

  68. Santillan JG, Mendieta H, Gomez LM, Torres JJ, González JM, Hernández LV, et al. The tetrad BMI, leptin, leptin/adiponectin (L/A) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal. 2013;27:12-20.

  69. Rack B, Andergassen U, Neugebauer J, Salmen J, Hepp P, Sommer H, et al. The German SUCCESS C study-the first European lifestyle study on breast cancer. Breast Care. 2010;5:395-400.

  70. Rock CL, Byers T, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, et al. Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) trial. Contemp Clin Trials. 2013;34:288-95.

  71. Untch M, Gerber B, Harbeck N, Jackisch Ch, Marschner N, Möbus V, et al. 13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus-Opinion of a German Team of Experts (Zurich 2013). Breast Care. 2013;8:221-9.

  72. Daniels SR. The use of BMI in the clinical setting. Pediatrics. 2009;124(suppl 1):S35-S41.

  73. Renehan AG. Obesity and cancer: clinical epidemiology. In: Bray GA & Bouchard C. Handbook of Obesity, Two Volume Set. Section 5. Vol 1. 3rd ed. Boca Raton: CRC Press Taylor and Francis Group; 2014. p. 561-72.




2020     |     www.medigraphic.com